Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK129 combinations in advanced solid tumors
NCT06943820Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AK129 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma and 1 more (9 arms), sponsored by Akeso, Inc. Primary endpoints: Adverse Events at 2 years and Overall Response Rate at 2 years. Started May 2025; status: recruiting.
02
Drugs
AK129
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)colorectal adenocarcinomasolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06943820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943820.